NCT04517838View on ClinicalTrials.gov

Immune Response to Anti-HER2 Therapies in Patients With HER2-Positive Stage I-IV Breast Cancer

RecruitingOBSERVATIONAL
Enrollment

230

Participants

Timeline

Start Date

July 31, 2020

Primary Completion Date

July 27, 2027

Study Completion Date

July 27, 2028

Conditions
Breast AdenocarcinomaHER2-Positive Breast CarcinomaAnatomic Stage I Breast Cancer AJCC v8Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8
Interventions
PROCEDURE

Biospecimen Collection

Undergo collection of blood and tumor tissue samples

Trial Locations (1)

32224-9980

RECRUITING

Mayo Clinic in Florida, Jacksonville

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
lead

Mayo Clinic

OTHER

NCT04517838 - Immune Response to Anti-HER2 Therapies in Patients With HER2-Positive Stage I-IV Breast Cancer | Biotech Hunter | Biotech Hunter